The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up
Abstract
PURPOSE: To investigate whether chemotherapy with etoposide and cisplatin (EP) is superior to cyclophosphamide, epirubicin, and vincristine (CEV) in small-cell lung cancer (SCLC). PATIENTS AND METHODS: A total of 436 eligible patients were randomized to chemotherapy with EP (n = 218) or CEV (n = 218). Patients were stratified according to extent of disease (limited disease [LD], n = 214; extensive disease [ED], n = 222). The EP group received five courses of etoposide 100 mg/m 2 intravenously (IV) and cisplatin 75 mg/m 2 IV on day 1, followed by oral etoposide 200 mg/m 2 daily on days 2 to 4. The CEV group received five courses of epirubicin 50 mg/m 2, cyclophosphamide 1,000 mg/m 2, and vincristine 2 mg, all IV on day 1. In addition, LD patients received thoracic radiotherapy concurrent with chemotherapy cycle 3, and those achieving complete remission during the treatment period received prophylactic cranial irradiation. RESULTS: The treatment groups were well balanced with regard to age, sex, and prognostic factors such as weight loss, and performance status. The 2- and 5-year survival rates in the EP arm (14% and 5%, P = .0004) were significantly higher compared with those in the CEV arm (6% and 2%). Among LD patients, median survival time was 14.5 months versus 9.7 months in the EP and CEV arms, respectively (P = .001). The 2- and 5-year survival rates of 25% and 10% in the EP arm compared with 8% and 3% in the CEV arm (P = .0001). For ED patients, there was no significant survival difference between the treatment arms. Quality-of-life assessments revealed no major differences between the randomized groups. CONCLUSION: EP is superior to CEV in LD-SCLC patients. In ED-SCLC patients, the benefits of EP and CEV chemotherapy seem equivalent, with similar survival time and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Self-citationInterpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
Aupérin, A., Arriagada, R., Pignon, J.-P., Le Péchoux, C., Gregor, A., Stephens, R. J., Kristjansen, P. E. G., Johnson, B. E., Ueoka, H., Wagner, H., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410703 · Cited by 1,718
Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., & Johnson, D. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400403 · Cited by 1,506
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer
Pignon, J.-P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., Brodin, O., Joss, R. A., Kies, M. S., Lebeau, B., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272302 · Cited by 1,331
Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 885
Self-citationWarde, P., & Payne, D. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.890 · Cited by 816
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
King, M. T. (1996) · Quality of Life Research · doi:10.1007/bf00439229 · Cited by 666
Roth, B. J., Johnson, D. H., Einhorn, L. H., Schacter, L. P., Cherng, N. C., Cohen, H. J., Crawford, J., Randolph, J. A., Goodlow, J. L., & Broun, G. O. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.282 · Cited by 556
Cited by
Owonikoko, T. K., Dahlberg, S. E., Sica, G. L., Wagner, L. I., Wade, J. L., Srkalovic, G., Lash, B. W., Leach, J. W., Leal, T. B., Aggarwal, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00264 · Cited by 185
Outcome based subgroup analysis: a neglected concern
Hirji, K. F., & Fagerland, M. W. (2009) · Trials · doi:10.1186/1745-6215-10-33 · Cited by 41
“[19] randomized small-cell lung cancer patients to etoposide and cisplatin (EC, n = 218) versus cyclophosphamide, epirubicin, and vincristine (CEV, n = 218).”
Background
Metadata
- Authors
- Sundstrøm, S., Bremnes, R. M., Kaasa, S., Aasebø, U., Hatlevoll, R., Dahle, R., Boye, N., Wang, M., Vigander, T., Vilsvik, J., Skovlund, E., Hannisdal, E., & Aamdal, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-12-15
- Volume
- 20
- Issue
- 24
- Pages
- 4665-4672
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150878803
- Cited by
- 499
- References
- 28
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. https://app.cochat.ai/papers/10.1200/jco.2002.12.111
- The paper
- Sundstrøm, S., Bremnes, R. M., Kaasa, S., Aasebø, U., Hatlevoll, R., Dahle, R., Boye, N., Wang, M., Vigander, T., Vilsvik, J., Skovlund, E., Hannisdal, E., & Aamdal, S. (2002). Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.12.111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
